Drugs / CD19-CAR\_Lenti
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06685042 | Nov 2024 → Dec 2025 overdue | anti-neutrophil cytoplasmic antibody-associated vasculitis, dermatomyositis, systemic lupus erythematosus, systemic sclerosis | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR\_Lenti | “CD19-CAR\_Lenti is a suspension of fresh CD4/CD8-enriched CD3+ T cells that have been genemodified with a self-inactivating (SIN) lentiviral vector expressing a CAR directed...” NCT06685042 ↗ |
| Action | Deplete | “B cell depletion” NCT06685042 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR T-cell therapy” NCT06685042 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT06685042 ↗ |
| Target | CD19 | “targeting CD19-positive B cells” NCT06685042 ↗ |